|
African Journal of Biomedical Research
Ibadan Biomedical Communications Group
ISSN: 1119-5096
Vol. 10, Num. 2, 2007, pp. 217 - 222
|
African Journal of Biomedical Research, Vol. 10, No. 3, 2007, pp. 217 - 222
Full
Length Research Article
Plasma Copper Status in
Hypercholesterolemic Patients
Soyinka,
Oluwatosin O1*; Anetor John I2; Ogundaunsi Omobola A1;
Adeniyi, Francis A2
1Department of
Chemical Pathology and Immunology, OACHS, Olabisi-Onabanjo University, Sagamu
campus, Ogun State, Nigeria.
2Department of
Chemical Pathology and Immunology, University of Ibadan, Nigeria.
*Address for Correspondence: Tel:+234 8037123058;e-mail: tosinsoyinka @ yahoo . com
Received: May
2007
Accepted
(Revised): July
2007
Published: September
2007
Code Number: md07030
ABSTRACT
There
has been inconsistent association between low copper (Cu) status and
hypercholesterolemia (Hypercholesterolemia is a known risk factor in coronary
heart disease). Most of these earlier studies have been predominantly in
experimental models; very few reports have examined human subjects. We
investigated the relationship between Cu status and hypercholesterolemia in
human subjects and if this relationship is established it may be amenable to
nutritional interventions. Seventy four (74) randomly selected plasma samples
from patients on which cholesterol (Chol) estimations had been previously
performed were included. The plasma samples were classified into three (3)
categories according to the cholesterol concentration based on the reference
range at UCH, Ibadan as at the time of analysis. The study groups included the
following, hypercholesterolemic group (group1) (Chol level, > 250mg/dl),
normocholesterolemic group (group2) (Chol level, 150 ≥ 250mg/dl); and
hypocholesterolemic group (group 3) (Chol level, 87- 149mg/dl). The mean values
of Cu in groups 1, 2, 3 were 103.39±8.58 µg/dl, 122.67±14.69µg/dl and
123.82±10.15µg/dl respectively. The mean concentration of Cu in
hypercholesterolemia was significantly different from the normocholesterolemia
(p< 0.0001) and the hypocholesterolemia (p< 0.0001) respectively. The
plasma Cu level of the hypercholesterolemic group was the lowest; while the
levels in the normocholesterolemic and the hypocholesterolemic groups were similar.The low level of Cu in the hypercholesterolemic
group was significantly lower than the levels in groups 2and 3 (p<0.0001) in
both cases. There was a significant inverse correlation between cholesterol and
Cu levels (r = - 0.4909; p< 0.0001). These data support some previous
reports that hypercholesterolemia is associated with decrease Cu status and
this may be manipulated to control hypercholesterolemia and associated
disorders.
Key
Words: hypercholesterolemia,
hypocholestrolemia, normocholesterolemia, copper, coronary heart disease.
INTRODUCTION
The
transition metal copper is an essential human micronutrient for enzymes that
catalyze oxidation - reduction reactions (Linder and Hazegh-Azam, 1996). Copper
has also been described as an antioxidant nutrient for cardiovascular health
(Allen et al, 1994). One of the nutrients associated with copper
metabolism is cholesterol. The latter plays a central role in many biomedical
processes but is best known for its association with cardiovascular disease.
Hypercholesterolemia is considered a major risk factor for the development of
atherosclerosis (Gotto, 1986). Diets low in copper also has been suggested as
an explanation for much of the epidemiology and pathophysiology of ischemic
heart disease (Klevay, 2000). For some authors, absolute copper deficiency could
be a risk factor in the etiology of cardiovascular diseases by altering lipid
metabolism (Thuiller- Jeteau et al, 1987). Furthermore copper deficiency
was claimed to be the only nutritional insult that elevates cholesterol (Klevay
et al, 1984). Hypercholesterolemia was also found to be one of the
similarities that exist between animals deficient in copper and people with
ischemic heart disease (Klevay, 1983). Copper deficiency is therefore offered
as the simplest and most general explanation for ischemic heart disease
(Klevay, 2000).
A
substantial decrease in liver copper concentration has been demonstrated after
feeding rats with a cholesterol-rich diet (Abu-el-Zahab 1991). Moreover feeding
rats a Copper deficient diet resulted in hypercholesterolemia (Al-Othman et al 1994;
Carr et al 1990). Biochemical
correlate of copper insufficiency included hyper-cholesterolemia when over 30
men and women were depleted of copper carefully with diets made with
conventional foods containing 0.65 to 1.02mg/day (Klevay et al, 1984;
Reiser et al 1987). Copper deficiencies from several species have
produced hypercholesterolemia in at least 22 independent laboratories worldwide
( klevay, 2000). Many people consume slightly less than the safe and adequate
range of copper, 1.5 3.0mg/ day though, frank copper deficiency is uncommon.
Deficiency can occur in people using zinc supplement without increasing copper
intake because zinc interferes with copper absorption (Sandstead, 1995).
The
study aims at investigating copper status in hypercholesterolemic patients and
to determine the relationship between copper and cholesterol metabolism, and if
this relationship is established copper deficiency may be amenable to
nutritional interventions.
MATERIALS AND
METHODS
Selection
of Subjects.
The study was carried out on seventy-four (74)
randomly selected plasma samples obtained from the Clinical Chemistry
Laboratory of the Department of Chemical Pathology, University College Hospital
(UCH), Ibadan. These samples were among the biological materials of subjects
referred to the laboratory for cholesterol estimation. The details of the
patients states of health, features such as age and sex were then traced to
their case records. Some of these could not be retrieved. The samples were
classified into three groups. Group 3 was made up of samples with cholesterol
values less than 150mg/dl (hypocholesterolemic) while group 2 consisted of
samples with cholesterol values within the local reference range as at the time
of analysis; these are values between 150 and 250 mg/dl (normocholesterolemic).
Group 1 included samples with cholesterol values greater than 250mg/dl
(hypercholesterolemic). Group 1, the hypercholesterolemic group, serves as the
study group while groups 2 and 3 were included for comparison.
Methods
Plasma cholesterol estimation was
performed using essentially the enzymatic method of Trinder (1969) on Boehringer
Mannheim Hitachi 704 Autoanalyser. (Boehringer Mannheim GmbH. D-68298 Mannheim
Germany). Plasma copper level was determined using atomic absorption
spectrophotometer (AAS), on Pye Unicam S.P. 90A series 2 (Pye Unicam Ltd.,
Cambridge, England). Plasma total protein level was determined by the Biuret
method (Reinhold, 1953) and albumin level in plasma was estimated using the
method of Doumas et al (1971). Statistical analyses were carried out
using Statpac Gold Statistical Analysis package. Students t- test was used to
compare means of two groups, while ANOVA was used to compare means involving
three groups. Pearsons correlation coefficient was used to establish
relationship between variables. Values of P<0.05 were considered
statistically significant.
RESULTS
Table1
shows the mean copper levels in hyper-cholesterolemic group 1,
normocholesterolemic group 2 and hypo-cholesterolemic group 3. The mean copper
level ranges from 103.39±8.58µg/dl to 123.85±10.75µg/dl. Group 1 demonstrated
the lowest mean copper value while group 3 demonstrated the highest mean copper
value, thus displaying an interesting trend of decrease in mean plasma copper
level from group 3 to1. When the mean copper levels of the various groups were
compared, a highly significant difference was exhibited (P < 0.0001). Table
2 shows further comparison of the mean copper level between groups 1 and 2, a
significant difference was observed, p<0.0001. Similarly
a significant difference was observed between groups 1 and 3 p<0.0001. Correlation of copper with cholesterol exhibited a
highly significant inverse relationship (r = -0.4909; p<0.0001) as shown in
table 3. Table 4 shows the correlation between Age, cholesterol and Copper.
Table
1
Comparison
of copper levels among hypercholesterolemic, normocholesterolemic and
hypocholesterolemic subjects (groups 1, 2 and 3)
Groups/sample No
|
copper level (µg/dl)*
|
F value
|
P value
|
hypercholesterolemic
(Group 1) (n=18)
|
103.39
±8.58
|
15.85
|
p<
0.0001
|
normocholesterolemic
(Group 2) (n=43)
|
122.67
±14.69
|
hypocholesterolemic
(Group3) (n=13)
|
123.82
±10.15
|
*
Values are mean ± SD; n=sample number
Table
2
Comparison
of copper levels between hypercholesterolemic and normocholesterolemic
subjects; and between hypercholesterolemic and hypocholesterolemic
subjects.
Groups
|
Copper (µg/dl)*
|
t- value
|
P value
|
Hypercholesterolemic
(Group 1)
Normocholesterolemic
(Group 2)
|
103.39±8.58
122.67±14.69
|
5.35
|
p<0.0001
|
Hypercholesterolemic
(Group1)
Hypocholesterolemic
(group3)
|
103.39±8.58
123.82±10.15
|
4.38
|
p<0.0001
|
*
Values are mean ± SD
Table
3
Simple
Correlation matrix between cholesterol, copper, total protein and Albumin
Biochemical
variables
|
Cholesterol
|
Total
Protein
|
Albumin
|
Total
Protein
|
r
= 0.3131
|
|
|
P
= NS (0.007)
|
|
|
Albumin
|
r
= 0.0782
|
r
= 0.3232
|
|
P
= NS (0.508)
|
P
= NS (0.005)
|
|
Copper
|
r
= -0.4909
|
r
= 0.1111
|
r
= -0.0601
|
P
=0.0000*
|
P
= NS (0.346)
|
P
= NS (0.611)
|
r
= correlation coefficient; P = P-value; *= Significant; NS= Not-significant
Table
4
Correlation
between Age, cholesterol and Copper
Age
|
Cholesterol
|
Copper
|
Age
(Mean
= 42.23 ± 15.05)
|
r
= 0.0138
|
r
= 03795
|
P
= NS
|
P
= NS
|
r
= correlation coefficient; P = P-value; NS= Not-significant
DISCUSSION
Association
between low copper status and hypercholesterolemia has been documented
consistently in experimental models (Allen and Klevay 1978; Harvey and Allen
1981; Croswell and Lei, 1985; Carr et al 1990; Al- Othman et al
1994; Bureau et al 2003). Clinical pursuits to ascertain similar effects
(or otherwise) among patients that are hypercholesterolemic is scanty.
This
study was designed therefore to examine copper status in hypercholesterolemic
patients so as to provide a basis for consideration of nutritional
interventions, which have been suggested by some investigators
(Alarcon-Corredor et al 2004; Galhardi et al, 2005). This study
is important because hypercholesterolemia is a risk factor of coronary heart
disease, which is a leading cause of death among many populations (Anon, 1967;
Gotto, 1986; Strain 1994; Anon, 2000; AIHW, 2002). It is therefore a relevant factor in the pursuit of
strategies for prevention or reduction of coronary heart disease through
nutritional interventions.
The
inverse relationship between copper and cholesterol levels observed in this
study is consistent with other studies (Klevay et al 1984; Klevay 1990a,
1990b, and 2000). Klevay has consistently demonstrated an inverse relationship
between cholesterol and copper metabolism. However several other investigators
have not been able to reproduce this association. Thuiller Jeteau et al
(1987) reported increased Cu status in hypercholesterolemia. Abiaka et al
(2003) observed that unlike in animal studies, copper excess in humans is
associated with hypercholesterolemia and therefore will predispose to
atherosclerosis. Aoyama et al (1999) observed that serum cholesterol did
not increase in rats fed with copper-deficient diets, though copper in serum
decreased markedly in rats. Bergomi et al (1997) found an inverse
correlation between lysyl oxidase activity in serum and both systolic and
diastolic blood pressure in untreated, mild essential hypertension. This can be
said to be indirectly consistent with this study because lysyl oxidase is a
copper enzyme (among many others) Klevay (2000) and hypercholesterolemia is a
risk factor of hypertension.
From
past studies, copper deficiency developed in experimental animals and also in
man, had resulted in hypercholesterolemia (Klevay et al, 1984; 2000).
Copper supplementation had also been found to reduce total cholesterol in rats
(Galhard et al 2005). According to Alarcon-Corredor et al 2004,
copper supplementation decreased serum total cholesterol in man. This study had
demonstrated reduced copper status in hypercholesterolemia, hence it
substantiates the fact that reduced copper status is associated with
hypercholesterolemia. There is therefore need to establish if with adequate
copper nutriture, hypercholesterolemia can be prevented, thus probably reducing
the risk of coronary heart disease.
One
of the suggested mechanisms of action between reduced copper status and
hypercholesterolemia is that copper deficiency increases the activity of
β-hydroxyl-β-methyl-glutarylCoA (HMG-CoA) reductase, This enzyme
catalyzes the rate limiting step in the biosynthetic pathway of cholesterol
from acetyl-CoA. The increased activity of the enzyme in the liver in copper
deficient rats corresponds with increased cholesterogenesis. It was thought
that more of this newly synthesized cholesterol may be channeled for the
synthesis of lipoproteins and their subsequent release into circulation thus
causing increase in plasma level. (Valzala et al 1987).
The
results of this study show an inverse relationship between copper and
cholesterol levels. The findings support the hypothesis that
hypercholesterolemia is associated with reduced copper status.
REFERENCES
- Abiaka,
C; Olusi, S; Al-Awadhi, A. (2003): Serum
microminerals and the indices of lipid metabolism in an apparently healthy
population. J. Clin. Lab. Anal. 17 (2), 61-5
- Abu-el-Zahab,
H.S., Abdel-Aal, W.E., Awadallah, R., Mikhail, T.M., and Zakaria, K. (1991): The correlation between serum total cholesterol and
some trace elements in serum, liver and heart of rats fed high cholesterol.
Nahrung 35(8), 827-34
- Alarcon-Corredor,
O.M., Guerrero, Y., Ramirez de fernandez ., DJesus I., Burguera, M et al
(2004): Effects of copper
supplementation on lipid profile of Venezuelan hyperlipedemic patients. Arch
Latinoam Nutr. 54 (4):413-8
- Allen,
K.G. and Klevay, L.M. (1994): Copper:
an antioxidant nutrient for cardiovascular health. Curr. Opin. Lipidol. 5 (1): 22-8
- Allen,
K.G. D. and Klevay, L.M. (1978): Copper
deficiency and cholesterol metabolism in the rat. Atherosclerosis 31,
259-271.
- Al-Othman,
A.A., Rosenstein, F., and Lei, K.Y. (1994): Pool size and concentration of plasma cholesterol are increased and
tissue copper levels are reduced during early stages of copper deficiency in
rats. J. Nutr. 124, 628-635.
- Anon
(2000): Cardiovascular disease ranks
as the first cause of death in Spain. Rev Esp Salud Publica 74 (3),
215-53.
- Anon.
(1967): Vital Statistics of the
United States. Mortality, Washington: U.S. Dept. Health, Educ. Wefare, 1969,
vol. 2, Part A, Tables 1-7.
- Aoyama
Y, Takagi M, Yoshida A. (1999) Lipid
alterations in the liver and serum of rats in histidine-excess and copper
deficiency. J. Nutr. Sc. Vitaminol (Tokyo) 45 (6), 773-83
- Australian
Institute of Health and Welfare (AIHW) (2002):Epidemic of coronary heart disease and its treatment in
Australia. Canberra Report No.:
AIHW cat. No. CVD 21. Available at:http://www.aihw.gov.au/publications/index.cfm/find/epidemic%20of%20coronary%20
heart%20disease
Accessed July 2004
Bergomi, M., Rovesti S.,
Vinceti M., Vivoli R., Caselgrandi, E., Viroli, G. (1997): Zinc and copper status and blood pressure. J. Trace Elem. Med. Biol. 11, 166-169.
- Bureau,
I., Gueux, E., Mazur, A., Rock, E., Roussel, A and Rayssiguier Y (2003): Female Rats are protected against oxidative stress
during copper deficiency. Journal of the American College of
Nutrition 22 (3), 239-246
- Carr,
T.P., and Lei, K.Y. (1990): High-density
lipoprotein cholesteryl ester and protein catabolism in hypercholesterolemic
rats induced by copper deficiency. Metabolism 39, 518-524.
- Croswell
S.C. and Lei, K.Y. (1985): Effect of
Copper Deficiency on the Apolipoprotein- E- rich High Density Lipoproteins in
Rats. J. Nutr. 115:473-482.
- Doumas,
B. T., Watson, W and Biggs, H. G. (1971): Albumin standards and the measurement of serum albumin with
bromocresol green. Clinica Chim. Acta. 31, 87-96.
- Galhardi
C.M., Diniz, Y.S., Rodrigues, H.G., Faine, L.A., Burneiko, R.C., Ribas, B.O.
and Novelli, E.L. (2005): Beneficial
effects of dietary copper supplementation on serum lipids and antioxidant
defenses in rats. Ann. Nutr. Metab. 49, 283-8
- Gotto
AM. Jr. 1986: Interaction of the
major risk factors for coronary heart disease. Am. J. Med. 14, 80 (2A):
48-55
- Harvey,
P.W. and Allen, K.G.D. (1981): Decreased plasma lecithin: cholesterol acyltransferase activity in copper
deficient rats. J. Nutr. 111, 1855-8.
- Klevay
L.M. 1990a: Ischemic heart disease as
copper defiency. Kies C. eds. Copper Bioavailability and metabolism Adv.
Exp. Med. Biol. 258, 197-208. Plenum Press New York, NY.
- Klevay
LM, Inman L., Johnson LK, Lawler M., Mahaiko JR., Milne DB., Lukaski HC., Bolonchuk
W., Sandstead HH (1984): Increased
cholesterol in plasma in a young man during experimental copper depletion. Metabolism
33,1112-1118.
- Klevay
LM. (2000): Dietary copper and risk
of coronary heart disease. American journal of clinical nutrition 71 (5),
1213-1214.
- Klevay
LM. (2000): Trace element and mineral
nutrition in disease: ischemic heart disease. In: Bogden JD, Klevay LM, eds.
Clinical nutrition of the essential trace elements and minerals: the guide for
health professionals. Totowa, NJ: Humana Press Inc: 25171.
- Klevay,
L.M. (1983): Copper and Ischemic
heart disease Biol. Trace Element Res. 5: 245-255
- Klevay,
L.M. (1990b): Ischemic heart disease:
toward a unified theory. Lei. K.Y. Carr T.P. eds. Role of copper in lipid
metabolism/ TITLE> 233- 267 CRC Press Bocs Raton, FL.
- Linder
MC, Hazegh-Azam M. (1996): Copper
biochemistry and molecular biology Am. J. Clin. Nutr. 63,797S-811S
- Reinhold.
J.G. (1953): Standard method of clinical chemistry, 1st ed. (Reiner, M. Ed.). New York. Academic Press. 1:88.
- Reiser
S., Powell A., Yang CY., Canary JJ (1987): Effect of copper intake on blood cholesterol and its lipoprotein
distribution in men. Nutr. Rep. Int. 36, 641- 649.
- Sandstead
HH. (1995): Requirements and toxicity
of essential trace elements, illustrated by zinc and copper. Am. J. Clin.
Nutr. 61: 621S-624S.
- Strain
(1994): Newer aspects of
micronutrients in chronic disease: copper. Proceedings of the Nutrition
Society. 53, 583-598
- Thuillier-Juteau
Y., Jaudon M.C., Clavel J.P., Delattre J., Galli. (1987): Serum zinc and copper in hypercholesterolemia. Pathol
Biol (Paris). (Apr) 35 (4): 387-90
- Trinder
P (1969): Ann. Clin. Biochem. 6, 24.
- Valzala,
P., Kurup P.A. (1987): Investigations
on mechanism of hypercholesterolemia observed in copper deficiency in rats J.
Biol. Sci. 12, 137.
- Wapnir,
R.A. (1998): Copper absorption and
bioavailability. Am. J. Clin. Nutr. 67 (Suppl.), 1054S-1060S.
© Ibadan Biomedical Communications Group
|